Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2012        Go!    
 
 
October 23, Monday 2017 6:11 AM       

       HEADLINES: Sangh Parivar will divide India using Taj Mahal as weapon: Thomas Isaac                                              Notice sent to Dileep seeking explanation on security agency                                              Lake encroachment: Collector’s report is against Thomas Chandy                                              Expel Thomas Chandy from cabinet, says Chennithala                                              I’ve not seen the report, says Revenue Minister                                              Zakir Naik to be chargesheeted by NIA                                              Opp. parties have no 'authority' to question EC: Modi                                              Modi Govt. is 'a government of excuses': Congress                                              Rajini says 'Mersal' has addressed important issue                                              Anti-terror squad kills eight suspects in Karachi                                              Zardari accuses Sharif brothers of planning his murder twice                                              Swaraj meets B'desh PM discusses Rohingya crisis                                              Third gold for Anumol                                              School sports meet: Thangjam Singh strikes triple                                              Kohli smashes 31st ODI ton, surpasses Ponting's record                                              Srikanth blows away Lee to win Denmark Open                                              Kaumudi Facebook
       SCI&TECH Next Article: Water exists deeper in Earth than thought: study  
       New potent vaccine may spell end for HIV
 
         Posted on :16:07:12 Nov 28, 2016
   
A A
       Last edited on:16:07:12 Nov 28, 2016
         Tags: New potent vaccine, HIV
 
WASHINGTON: The largest and most advanced HIV vaccine trial has been launched in South Africa to test the safety of a new experimental regimen that could prove to be the final nail in the coffin for the deadly virus.
 
The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus.
 
It aims to enroll 5,400 men and women, making it the where more than 1,000 people become infected with HIV every day.
 
"If deployed alongside our current armory of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," said Anthony S Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID).
 
"Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa," said Fauci.
 
The HIV Vaccine Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020.
 
The experimental vaccine regimen being tested in the trial is based on the one investigated in the earlier RV144 clinical trial in Thailand led by the US Military HIV Research Programme and the Thai Ministry of Health.
 
The Thai trial delivered landmark results in 2009 when it found for the first time that a vaccine could prevent HIV infection, albeit modestly.
 
The new regimen aims to provide greater and more sustained protection than the RV144 regimen and has been adapted to the HIV subtype that predominates in southern Africa, a region that includes the country of South Africa.
 
"The people of South Africa are making history by conducting and participating in the first HIV vaccine efficacy study to build on the results of the Thai trial," said Glenda Gray, CEO of the South African Medical Research Council.
 
"HIV has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country," Gray said, who is also a professor at the University of the Witwatersrand.
 
"If an HIV vaccine were found to work in South Africa, it may dramatically alter the course of the pandemic," she said. The experimental vaccine regimen tested in the Thai trial was found to be 31.2 per cent effective at preventing HIV infection over the 3.5-year follow-up after vaccination.
 
In the HVTN 702 study, the design, schedule and components of the RV144 vaccine regimen have been modified in an attempt to increase the magnitude and duration of vaccine-elicited protective immune responses.
 
HVTN 702 begins just months after interim results were reported for HVTN 100, its predecessor clinical trial, which found that the new vaccine regimen was safe for the 252 study participants and induced comparable immune responses to those reported in RV144. 
A A
       SCI&TECH
Next Article: Water exists deeper in Earth than thought: study
 
 
SCI&TECH HEADLINES
Suicide molecules may help combat cancer: Study  
Aspirin a day may keep liver cancer away  
Clearing the myths about osteoporosis  
Stress as unhealthy as junk food  
Planet Nine does exist in solar system: NASA  
Blame these hormones if your dog is getting aggressive  
Save big on Infinix Note 4, Hot 4 Pro during Flipkart's 'Big Diwali Sale'  
Even modest exposure to oil can harm coastal, marine birds  
Starfish, anemones protect ecosystems from climate change  
Skipping breakfast may help to shed those extra kilos  
Dozing off during lecture? Blame your neurons  
Google's Pixel 2 promotes safe driving through automatic 'do not disturb' mode  
Researchers create molecule that could kill HIV  
Google unveils new moves to boost struggling news organizations  
Here's how zebrafish get its stripes  
Facebook to introduce facial recognition for account security  
LG launches smartphone to 'keep mosquitos at bay'  
New spider species named after DiCaprio, Obama  
Astrophysicists make music from Saturn's moons, rings  
Rooter includes Kabbadi, F1 under one roof  
Orbiting supermassive black holes discovered for first time  
Theweightmonitor.com launches mobile app for easier access to one-stop weight management platform  
New drug to treat blood cancer developed  
Threat of asteroid impact looming over Earth: experts  
Hottest known planet in universe discovered  
 
Should Kummanam apologise to Kerala as remarked by the CM?
yes
 
no
 
no opinion
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy